查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813856

SGLT2抑制剂市场规模、份额和趋势分析报告：按药物、适应症、分销管道、地区和细分市场预测，2025-2033年

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Type 2 Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

SGLT2抑制剂市场摘要

预计 2024 年全球 SGLT2 抑制剂市场价值将达到 168 亿美元，2033 年将达到 289 亿美元，2025 年至 2033 年的复合年增长率为 6.19%。

这些用于治疗 2 型糖尿病和合併症的药物因其在控制血糖和降低心血管风险方面的有效性而需求量很大。

由于全球 2 型糖尿病以及心血管疾病和慢性肾臟病等合併症的盛行率不断上升，市场正在经历显着增长。根据国际糖尿病联盟 (IDF) 的数据，2024 年全球约有 5.89 亿成年人将罹患糖尿病，预计到 2050 年将增加至 8.53 亿人。日益加重的糖尿病负担促使医疗系统寻求更有效的治疗方法，其中 SGLT2 抑制剂因其控制血糖和保护心血管的双重益处而广受欢迎。这些药物，例如Empagliflozin和Dapagliflozin，在减少糖尿病患者心血管死亡和因心臟衰竭住院方面显示出显着益处。此外，SGLT2 抑制剂在治疗慢性肾臟病中的作用越来越受到认可，这推动了进一步的市场需求，FDA核准Dapagliflozin用于治疗非糖尿病患者的慢性肾臟病是 2020 年的主要适应症扩展。

目录

第一章调查方法与范围

第二章执行摘要

3. SGLT2抑制剂市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • SGLT2抑制剂市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析
    • 目标人群分析

第四章 SGLT2抑制剂市场：药物估价与趋势分析

  • 全球 SGLT2 抑制剂市场：製药仪表板
  • 全球SGLT2抑制剂市场：药物变异分析
  • 全球 SGLT2 抑制剂市场（按药物和收益）
  • Jardiance（Empagliflozin）
  • Farxiga（Dapagliflozin）
  • Invokana（Canagliflozin）
  • Impefa（索格列净）
  • Qtern（Dapagliflozin/沙格列汀）
  • 其他SGLT2抑制剂

第五章 SGLT2抑制剂市场：适应症与趋势分析

  • 全球 SGLT2 抑制剂市场：适应症仪表板
  • 全球SGLT2抑制剂市场：适应症差异分析
  • 按适应症分類的收益
  • 2型糖尿病
  • 心血管系统
  • 慢性肾臟病（CKD）
  • 其他的

第六章：SGLT2抑制剂市场：通路评估与趋势分析

  • 全球 SGLT2 抑制剂市场：分销通路仪表板
  • 全球 SGLT2 抑制剂市场：通路变化分析
  • 按分销管道分類的收益
  • 医院药房
  • 零售药局
  • 网路药局

7. SGLT2抑制剂市场：按药物、适应症和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 市场规模、预测趋势分析，2021-2033年：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2023
    • Boehringer Ingelheim International GmbH.
    • AstraZeneca
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.（Janssen Pharmaceuticals, Inc.）
    • TheracosBio, LLC
    • Lexicon Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Glenmark Pharmaceuticals Ltd
Product Code: GVR-4-68040-322-4

SGLT2 Inhibitors Market Summary

The global SGLT2 inhibitors market size was estimated at USD 16.8 billion in 2024 and is projected to reach USD 28.9 billion by 2033, growing at a CAGR of 6.19% from 2025 to 2033. These drugs, used for Type 2 diabetes and comorbidities, are in high demand due to their effectiveness in glycemic control and cardiovascular risk reduction.

The market is experiencing significant growth due to the increasing global prevalence of Type 2 diabetes, along with related comorbidities such as cardiovascular diseases and chronic kidney disease. According to the International Diabetes Federation (IDF), nearly 589 million adults worldwide were living with diabetes in 2024, a figure that is expected to rise to 853 million by 2050. This growing burden of diabetes is prompting healthcare systems to seek more effective treatment options, with SGLT2 inhibitors gaining popularity due to their dual benefits of glycemic control and cardiovascular protection. These drugs, such as empagliflozin and dapagliflozin, have shown significant efficacy in reducing cardiovascular mortality and hospitalizations for heart failure in diabetic patients. Furthermore, the increasing recognition of the role of SGLT2 inhibitors in treating chronic kidney disease is driving further market demand, with the FDA's approval of dapagliflozin for chronic kidney disease in non-diabetic patients marking a notable expansion of its indications in 2020.

Global SGLT2 Inhibitors Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global SGLT2 Inhibitors market report based on drug, indication, distribution channel,and region:

  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Jardiance (empagliflozin)
  • Farxiga (dapagliflozin)
  • Invokana (canagliflozin)
  • Inpefa (sotagliflozin)
  • Qtern (dapagliflozin/saxagliptin)
  • Other SGLT2 Inhibitors
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Type 2 Diabetes
  • Cardiovascular
  • Chronic Kidney Disease (CKD)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Kuwait
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug and Indication outlook
    • 2.2.2. Distribution Channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of target disease
      • 3.2.1.2. Technological advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of drug development
      • 3.2.2.2. Stringent regulatory policies for drug approval
  • 3.3. SGLT2 Inhibitors Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

  • 4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
  • 4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
  • 4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
  • 4.4. Jardiance (empagliflozin)
    • 4.4.1. Jardiance (empagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Farxiga (dapagliflozin)
    • 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Invokana (canagliflozin)
    • 4.6.1. Invokana (canagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7. Inpefa (sotagliflozin)
    • 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8. Qtern (dapagliflozin/saxagliptin)
    • 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.9. Other SGLT2 Inhibitors
    • 4.9.1. Other SGLT2 inhibitors market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

  • 5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
  • 5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
  • 5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
  • 5.4. Type 2 Diabetes
    • 5.4.1. Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Cardiovascular
    • 5.5.1. Cardiovascular market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Chronic Kidney Disease (CKD)
    • 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
  • 6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
  • 6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Boehringer Ingelheim International GmbH.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. AstraZeneca
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. TheracosBio, LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lexicon Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Eli Lilly and Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Bristol-Myers Squibb Company
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Glenmark Pharmaceuticals Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 4 North America SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 U.S. SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 7 U.S. SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 Canada SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 10 Canada SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 12 Mexico SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 13 Mexico SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 17 Europe SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 19 Germany SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 20 Germany SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 UK SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 23 UK SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 France SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 26 France SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 27 France SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Italy SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 29 Italy SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 31 Spain SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 32 Spain SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Denmark SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 35 Denmark SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Sweden SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 38 Sweden SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 40 Norway SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 41 Norway SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 China SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 48 China SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 49 China SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Japan SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 51 Japan SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 53 India SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 54 India SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 55 India SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 South Korea SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 57 South Korea SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 Australia SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 60 Australia SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Thailand SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 63 Thailand SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Latin America SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 67 Latin America SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 69 Brazil SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 70 Brazil SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 72 Argentina SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 73 Argentina SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 MEA SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 77 MEA SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 South Africa SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 80 South Africa SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 85 UAE SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 86 UAE SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
  • Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
  • Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 SGLT2 Inhibitors market: market outlook
  • Fig. 14 SGLT2 Inhibitors competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 SGLT2 Inhibitors market driver impact
  • Fig. 18 SGLT2 Inhibitors market restraint impact
  • Fig. 19 SGLT2 Inhibitors market: Drug movement analysis
  • Fig. 20 SGLT2 Inhibitors market: Drug outlook and key takeaways
  • Fig. 21 Jardiance (empagliflozin) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Farxiga (dapagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Steglatro (ertugliflozin) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Invokana (canagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Brenzavvy (bexagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Inpefa (sotagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Other SGLT2 inhibitors estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 SGLT2 Inhibitors market: Indication movement analysis
  • Fig. 29 SGLT2 Inhibitors market: Indication outlook and key takeaways
  • Fig. 30 Type 2 diabetes market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Cardiovascular market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Chronic kidney disease (CKD) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 SGLT2 Inhibitors market: Distribution channel movement analysis
  • Fig. 35 SGLT2 Inhibitors market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Retail pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 38 Online pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 39 Global SGLT2 Inhibitors market: Regional movement analysis
  • Fig. 40 Global SGLT2 Inhibitors market: Regional outlook and key takeaways
  • Fig. 41 Global SGLT2 Inhibitors market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Market share of key market players - SGLT2 Inhibitors market